Assembly Biosciences to present hepatitis delta drug data at EASL congress
Tweet Send to a Friend
Assembly Biosciences Inc. (NASDAQ: ASMB) announced it will present topline Phase 1a clinical data on ABI-6250, an investigational oral hepatitis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
